| 臺大學術典藏 |
2020-07-21T06:09:13Z |
Modulating chemotaxis of lung cancer cells by using electric fields in a microfluidic device
|
Kao Y.-C.;Hsieh M.-H.;Liu C.-C.;Pan H.-J.;Wei-Yu Liao;Cheng J.-Y.;Kuo P.-L.;Lee C.-H.; Kao Y.-C.; Hsieh M.-H.; Liu C.-C.; Pan H.-J.; WEI-YU LIAO; Cheng J.-Y.; Kuo P.-L.; Lee C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:13Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Yang J.C.-H.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yang P.-C.; Chen H.-Y.; Hsu W.-H.; Lin Y.-L.; Lee J.-H.; Lee J.-H.;Lin Y.-L.;Hsu W.-H.;Chen H.-Y.;Chang Y.-C.;Yu C.-J.;Shih J.-Y.;Lin C.-C.;Chen K.-Y.;Ho C.-C.;Wei-Yu Liao;Yang P.-C.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:13Z |
Quality of life and related factors in patients with newly diagnosed advanced lung cancer: A longitudinal study
|
Liao Y.-C.; Shun S.-C.; WEI-YU LIAO; Yu C.-J.; Yang P.-C.; Lai Y.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:12Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Yang P.-C.; Lee C.-H.; Yu C.-J.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y.; Chen H.-Y.; Lee Y.-C.; Ho C.-C.; WEI-YU LIAO |
| 臺大學術典藏 |
2020-07-21T06:09:12Z |
GM2-activator protein: A new biomarker for lung cancer
|
Potprommanee L.; Ma H.-T.; Shank L.; Juan Y.-H.; WEI-YU LIAO; Chen S.-T.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:11Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; WEI-YU LIAO; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C.; Chen H.-J.; Wu T.-C.; Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M. |
| 臺大學術典藏 |
2020-07-21T06:09:11Z |
Discordant HER2 Exon 20 mutation status determines a differential sensitivity to Afatinib
|
Liu Y.-N.; Shih J.-Y.; WEI-YU LIAO; Gow C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:10Z |
Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases
|
Keng L.-T.; Lee H.-S.; Chang H.-T.; WEI-YU LIAO; Ho C.-C.; Yu C.-J.; Hsieh S.-C.; Lin C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:10Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.;Molina-Vila M.A.;Ruan S.-Y.;Su K.-Y.;Wei-Yu Liao;Yu K.-L.;Ho C.-C.;Shih J.-Y.;Yu C.-J.;Yang J.C.H.;Rosell R.;Yang P.-C.; Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; WEI-YU LIAO; Yu K.-L.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
Chih-Hsin Yang J.; Yu C.-J.; Ho C.-C.;Wei-Yu Liao;Lin C.-A.;Shih J.-Y.;Yu C.-J.;Chih-Hsin Yang J.; Ho C.-C.; WEI-YU LIAO; Lin C.-A.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study
|
Hsieh M.-J.; Wu W.-S.; Chen Y.-M.; Tsai Y.-H.; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; WEI-YU LIAO; Liu C.-Y.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Hsu K.-H.; Yu C.-J.; Yang C.-T.; Tseng C.-H.; Chang G.-C.; Chang G.-C.;Tseng C.-H.;Hsu K.-H.;Yu C.-J.;Yang C.-T.;Chen K.-C.;Yang T.-Y.;Tseng J.-S.;Liu C.-Y.;Wei-Yu Liao;Hsia T.-C.;Tu C.-Y.;Lin M.-C.;Tsai Y.-H.;Hsieh M.-J.;Wu W.-S.;Chen Y.-M. |
| 臺大學術典藏 |
2020-07-21T06:09:08Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Wei-Yu Liao;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; WEI-YU LIAO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:07Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Hsu F.-M.; Yang P.-C.; Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Wei-Yu Liao;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; WEI-YU LIAO; Yu C.-J.; Yang J.C.-H.; Cheng J.C.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:06Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Wei-Yu Liao;Ho C.-C.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Lee M.-R.; WEI-YU LIAO; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:06Z |
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
|
Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Wei-Yu Liao;Ho C.-C.;Tsai T.-H.;Chen K.-Y.;Shih J.-Y.;Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:06Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
|
Shih J.-Y.; Ho C.-C.; Wu T.-H.;Hsiue E.H.-C.;Lee J.-H.;Lin C.-C.;Wei-Yu Liao;Ho C.-C.;Shih J.-Y.;Yu C.-J.;Yang J.C.-H.; Wu T.-H.; Hsiue E.H.-C.; Lee J.-H.; Lin C.-C.; WEI-YU LIAO; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:05Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
Yu K.-L.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Lin C.-K.; Hsu C.-L.; Shih J.-Y.; Yu K.-L.;Tsai T.-H.;Ho C.-C.;Wei-Yu Liao;Lin C.-K.;Hsu C.-L.;Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Consecutive emergence of typical acquired resistance to EGFR tyrosine kinase inhibitors in a patient with metastatic pulmonary squamous cell carcinoma
|
Yu C.-J.; Shih J.-Y.; WEI-YU LIAO; Hsieh M.-S.; Yang C.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
|
Thress K.; Yang J.C.-H.; Stetson D.; Markovets A.; WEI-YU LIAO; Liao B.-C.; Hsu C.-C.; Hsu C.-C.;Liao B.-C.;Wei-Yu Liao;Markovets A.;Stetson D.;Thress K.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C. |
| 臺大學術典藏 |
2020-07-21T06:09:02Z |
Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells
|
Hou H.-H.;Pan H.-J.;Wei-Yu Liao;Lee C.-H.;Yu C.-J.; Hou H.-H.; Pan H.-J.; WEI-YU LIAO; Lee C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-04-08T10:35:55Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chia-Chi Hsu; Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Chia-Chi Lin; Jin-Yuan Shih; James C.-H. Yang; Chong-Jen Yu; Ching-Yao Yang; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Tzu-Hsiu Tsai; Chia-Lin Hsu; Kang-Yi Su; Yih-Leong Chang; Chen-Tu Wu; Chong-Jen Yu;James C.-H. Yang;Jin-Yuan Shih;Chia-Chi Lin;Jih-Hsiang Lee;Wei-Hsun Hsu;Bin-Chi Liao;Chia-Chi Hsu;Chen-Tu Wu;Yih-Leong Chang;Kang-Yi Su;Chia-Lin Hsu;Tzu-Hsiu Tsai;Kuan-Yu Chen;Chao-Chi Ho;Wei-Yu Liao;Ching-Yao Yang |
| 臺大學術典藏 |
2020 |
Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer
|
Lin W.-C.; Chuang C.-A.; WEI-YU LIAO; Lai C.-F.; Cho S.-L.; Cho S.-L.;Lin W.-C.;Chuang C.-A.;Wei-Yu Liao;Lai C.-F. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2019-03-04T08:13:58Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin, Shu Yung;Yang, Ching Yao;Bin-Chi Liao;Chao-Chi Ho;Wei-Yu Liao;Chen, Kuan-Yu;Tsai, Tzu Hsiu;Chia-Lin Hsu;Hsu, Wei Hsun;Kang-Yi Su;Yih-Leong Chang;Lee, Jih Hsiang;Lin, Chia Chi;Jin-Yuan Shih;Yang, James Chih Hsin;Chong-Jen Yu; Lin, Shu Yung; Yang, Ching Yao; BIN-CHI LIAO; CHAO-CHI HO; WEI-YU LIAO; Chen, Kuan-Yu; Tsai, Tzu Hsiu; CHIA-LIN HSU; Hsu, Wei Hsun; KANG-YI SU; YIH-LEONG CHANG; Lee, Jih Hsiang; Lin, Chia Chi; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2019-03-04T08:10:37Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
Lin, Ching Kai;Tsai, Tzu Hsiu;JIN-YUAN SHIH;CHIA-LIN HSU;WEI-YU LIAO;CHAO-CHI HO;KAI-LUN YU; KAI-LUN YU; Tsai, Tzu Hsiu; CHAO-CHI HO; WEI-YU LIAO; Lin, Ching Kai; CHIA-LIN HSU; JIN-YUAN SHIH |
| 臺大學術典藏 |
2019-03-04T08:06:47Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
|
Sheng-Kai Liang;Meng-Rui Lee;Wei-Yu Liao;Chao-Chi Ho;Jen-Chung Ko;Jin-Yuan Shih; SHENG-KAI LIANG; MENG-RUI LEE; WEI-YU LIAO; CHAO-CHI HO; JEN-CHUNG KO; JIN-YUAN SHIH |
| 臺大學術典藏 |
2019-03-04T08:04:19Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
CHONG-JEN YU; CHAO-CHI HO; WEI-YU LIAO; Lee, Jih Hsing; Tsai, Tzu Hsiu; KANG-YI SU; MIN-SHU HSIEH; YIH-LEONG CHANG; Bai, Ya Ying; Huang, Derek De Rui; Thress, Kenneth S.; CHIH-HSIN YANG; JIN-YUAN SHIH; Lin, Chia Chi; Thress, Kenneth S.;Huang, Derek De Rui;Bai, Ya Ying;Lee, Jih Hsing;Lin, Chia Chi;CHIH-HSIN YANG;YIH-LEONG CHANG;MIN-SHU HSIEH;KANG-YI SU;Tsai, Tzu Hsiu;WEI-YU LIAO;CHAO-CHI HO;CHONG-JEN YU;JIN-YUAN SHIH |
| 臺大學術典藏 |
2019-03-04T07:47:57Z |
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
|
Chen, Kuan-Yu;Tsai, Tzu Hsiu;CHONG-JEN YU;JIN-YUAN SHIH;CHAO-CHI HO;WEI-YU LIAO; WEI-YU LIAO; CHAO-CHI HO; Tsai, Tzu Hsiu; Chen, Kuan-Yu; JIN-YUAN SHIH; Chong-Jen Yu |
| 臺大學術典藏 |
2019-03-04T07:33:42Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang, Gee Chen;Cseh, Agnieszka;Carrière, Philippe;Lorence, Robert M.;Chih-Hsin Yang, James;Unk, Mojca;Spataro, Vito;Gautschi, Oliver;Nechushtan, Hovav;Curioni-Fontecedro, Alessandra;Peters, Solange;WEI-YU LIAO;JIN-YUAN SHIH; Peters, Solange; Curioni-Fontecedro, Alessandra; Nechushtan, Hovav; JIN-YUAN SHIH; WEI-YU LIAO; Gautschi, Oliver; Spataro, Vito; Unk, Mojca; Chih-Hsin Yang, James; Lorence, Robert M.; Carri?re, Philippe; Cseh, Agnieszka; Chang, Gee Chen |
| 臺大學術典藏 |
2019-03-04T06:51:46Z |
Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma
|
Yang, Ching-Yao;CHONG-JEN YU;JIN-YUAN SHIH;WEI-YU LIAO;MIN-SHU HSIEH; Yang, Ching-Yao; MIN-SHU HSIEH; WEI-YU LIAO; JIN-YUAN SHIH; Chong-Jen Yu |
| 臺大學術典藏 |
2019-03-04T06:50:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang, James Chih Hsin;Lin, Zhong Zhe;Lee, Jih Hsiang;Yang, Ching Yao;Lin, Yen Ting;Chen, Kuan-Yu;CHONG-JEN YU;JIN-YUAN SHIH;CHIA-LIN HSU;CHAO-CHI HO;WEI-YU LIAO;JIN-SHING CHEN; Lin, Yen Ting; JIN-SHING CHEN; WEI-YU LIAO; CHAO-CHI HO; CHIA-LIN HSU; Yang, Ching Yao; Chen, Kuan-Yu; Lee, Jih Hsiang; Lin, Zhong Zhe; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Shih J.-Y.; WEI-YU LIAO; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Wei-Yu Liao;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2018-09-10T18:07:07Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang, S.-K. and Lee, M.-R. and Liao, W.-Y. and Ho, C.-C. and Ko, J.-C. and Shih, J.-Y.; MENG RUI LEE; Wei-Yu Liao; Chao-Chi Ho; Jin-Yuan Shih; JEN-CHUNG KO; SHENG-KAI LIANG |
| 臺大學術典藏 |
2018-09-10T18:06:03Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang, W.-C. and Xiao, F. and Shih, J.-Y. and Ho, C.-C. and Chen, Y.-F. and Tseng, H.-M. and Chen, K.-Y. and Liao, W.-Y. and Yu, C.-J. and Yang, J.C.-H. and Kuo, S.-H. and Cheng, J.C.-H. and Yang, P.-C. and Hsu, F.-M.; Chong-Jen Yu; WEI-YU LIAO; FU-REN XIAO; YA-FANG CHEN; JIN-YUAN SHIH |
| 臺大學術典藏 |
2018-09-10T18:05:26Z |
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
|
Liao, W.-Y. and Ho, C.-C. and Tsai, T.-H. and Chen, K.-Y. and Shih, J.-Y. and Yu, C.-J.; WEI-YU LIAO |
| 臺大學術典藏 |
2018-09-10T18:05:26Z |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
WEI-YU LIAO; Chong-Jen Yu; JIN-YUAN SHIH; Ho, C.-C. and Liao, W.-Y. and Lin, C.-A. and Shih, J.-Y. and Yu, C.-J. and Chih-Hsin Yang, J. |
| 臺大學術典藏 |
2018-09-10T18:05:25Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients
|
Wu, T.-H. and Hsiue, E.H.C. and Lee, J.-H. and Lin, C.-C. and Liao, W.-Y. and Ho, C.-C. and Shih, J.-Y. and Yu, C.-J. and Yang, J.C.H.; WEI-YU LIAO |
| 臺大學術典藏 |
2018-09-10T18:04:10Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao, Z.-H. and Liao, W.-Y. and Ho, C.-C. and Chen, K.-Y. and Shih, J.-Y. and Chen, J.-S. and Lin, Z.-Z. and Lin, C.-C. and Yang, J.C.H. and Yu, C.-J.; Chong-Jen Yu; WEI-YU LIAO; JIN-YUAN SHIH; JIN-SHING CHEN |
| 臺大學術典藏 |
2018-09-10T18:03:16Z |
Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study
|
Liao, Y.-C. and Liao, W.-Y. and Sun, J.-L. and Ko, J.-C. and Yu, C.-J.; CHONG-JEN YU; WEI-YU LIAO; JEN-CHUNG KO |
| 臺大學術典藏 |
2018-09-10T18:00:50Z |
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer �V A multicenter retrospective SEQUENCE study
|
Chang, G.-C. and Tseng, C.-H. and Hsu, K.-H. and Yu, C.-J. and Yang, C.-T. and Chen, K.-C. and Yang, T.-Y. and Tseng, J.-S. and Liu, C.-Y. and Liao, W.-Y. and Hsia, T.-C. and Tu, C.-Y. and Lin, M.-C. and Tsai, Y.-H. and Hsieh, M.-J. and Wu, W.-S. and Chen, Y.-M.; CHONG-JEN YU; WEI-YU LIAO |
| 臺大學術典藏 |
2018-09-10T15:38:24Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
楊志新;蘇剛毅;廖唯昱;余忠仁;何肇基;阮聖元;施金元; 楊志新;蘇剛毅;廖唯昱;余忠仁;何肇基;阮聖元;施金元; Chen, Li-Yang; Chen, Li-Yang; Chong-Jen Yu; Molina-Vila, Miguel A.; WEI-YU LIAO; KAI-LUN YU; Ruan, Sheng-Yuan; Ruan, Sheng-Yuan; Ruan, Sheng-Yuan; Su, Kang-Yi; Su, Kang-Yi; CHAO-CHI HO; KANG-YI SU; Liao, Wei-Yu; Liao, Wei-Yu; Yu, Kai-Lun; Yu, Kai-Lun; JIN-YUAN SHIH; Yu, Kai-Lun; Ho, Chao-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Shih, Jin-Yuan; Shih, Jin-Yuan; Yu, Chong-Jen; Yu, Chong-Jen; Yang, James Chih-Hsin; Yang, James Chih-Hsin; Rosell, Rafael; Rosell, Rafael; Yang, Pan-Chyr; Yang, Pan-Chyr; Yang, Pan-Chyr; Chen, Li-Yang;Molina-Vila, Miguel A.;Ruan, Sheng-Yuan;Su, Kang-Yi;Liao, Wei-Yu;Yu, Kai-Lun;Ho, Chao-Chi;Shih, Jin-Yuan;Yu, Chong-Jen;Yang, James Chih-Hsin;Rosell, Rafael;Yang, Pan-Chyr; Chen, L.-Y. and Molina-Vila, M.A. and Ruan, S.-Y. and Su, K.-Y. and Liao, W.-Y. and Yu, K.-L. and Ho, C.-C. and Shih, J.-Y. and Yu, C.-J. and Yang, J.C.H. and Rosell, R. and Yang, P.-C. |
| 臺大學術典藏 |
2018-09-10T15:34:44Z |
The unmet supportive care needs—what advanced lung cancer patients’ caregivers need and related factors
|
Chen, S.-C.;Chiou, S.-C.;Yu, C.-J.;Lee, Y.-H.;Liao, W.-Y.;Hsieh, P.-Y.;Jhang, S.-Y.;Lai, Y.-H.; Chong-Jen Yu; WEI-YU LIAO; YUN-HSIANG LEE |
| 臺大學術典藏 |
2018-09-10T15:34:43Z |
Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases
|
Lin, C.-H. and Hsieh, S.-C. and Keng, L.-T. and Lee, H.-S. and Chang, H.-T. and Liao, W.-Y. and Ho, C.-C. and Yu, C.-J.; Chong-Jen Yu; WEI-YU LIAO; CHAO-CHI HO; KENG LI-TA |
| 臺大學術典藏 |
2018-09-10T15:27:22Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
|
Hsu, Kuo-Hsuan;Ho, Chao-Chi;Hsia, Te-Chun;Tseng, Jeng-Sen;Su, Kang-Yi;Wu, Ming-Fang;Chiu, Kuo-Liang;Yang, Tsung-Ying;Chen, Kun-Chieh;Ooi, Hean;Wu, Tzu-Chin;Chen, Hung-Jen;Chen, Hsuan-Yu;Chang, Chi-Sheng;Hsu, Chung-Ping;Hsia, Jiun-Yi;Chuang, Cheng-Yen;Lin, Chin-Hung;Chen, Jeremy J. W.;Chen, Kuan-Yu;Liao, Wei-Yu;Shih, Jin-Yuan;Yu, Sung-Liang;Yu, Chong-Jen;Yang, Pan-Chyr;Chang, Gee-Chen; Hsu, K.-H. and Ho, C.-C. and Hsia, T.-C. and Tseng, J.-S. and Su, K.-Y. and Wu, M.-F. and Chiu, K.-L. and Yang, T.-Y. and Chen, K.-C. and Ooi, H. and Wu, T.-C. and Chen, H.-J. and Chen, H.-Y. and Chang, C.-S. and Hsu, C.-P. and Hsia, J.-Y. and Chuang, C.-Y. and Lin, C.-H. and Chen, J.J.W. and Chen, K.-Y. and Liao, W.-Y. and Shih, J.-Y. and Yu, S.-L. and Yu, C.-J. and Yang, P.-C. and Chang, G.-C.; 俞松良;蘇剛毅;楊泮池;廖唯昱;陳冠宇;余忠仁;何肇基;施金元; Hsu, Kuo-Hsuan; SUNG-LIANG YU; Ho, Chao-Chi; Chong-Jen Yu; Hsia, Te-Chun; WEI-YU LIAO; Tseng, Jeng-Sen; KANG-YI SU; JIN-YUAN SHIH; Su, Kang-Yi; Wu, Ming-Fang; Chiu, Kuo-Liang; Yang, Tsung-Ying; Chen, Kun-Chieh; Ooi, Hean; Wu, Tzu-Chin; Chen, Hung-Jen; Chen, Hsuan-Yu; Chang, Chi-Sheng; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chuang, Cheng-Yen; Lin, Chin-Hung; Chen, Jeremy J. W.; Chen, Kuan-Yu; Liao, Wei-Yu; Shih, Jin-Yuan; Yu, Sung-Liang; Yu, Chong-Jen; Yang, Pan-Chyr; Chang, Gee-Chen |
| 臺大學術典藏 |
2018-09-10T15:24:44Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Ho, Chao-Chi; Hsia, Te-Chun; Su, Kang-Yi; Wu, Ming-Fang; Chiu, Kuo-Liang; Liu, Chien-Ming; Wu, Tzu-Chin; Chen, Hung-Jen; Chen, Hsuan-Yu; Chang, Chi-Sheng; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chuang, Cheng-Yen; Lin, Chin-Hung; Chen, Jeremy J. W.; Chen, Kuan-Yu; Liao, Wei-Yu; Shih, Jin-Yuan; Yu, Sung-Liang; Yu, Chong-Jen; Yang, Pan-Chyr; Yang, Tsung-Ying; Chang, Gee-Chen; Tseng, Chien-Hua; 楊泮池; SUNG-LIANG YU; WEI-YU LIAO; CHONG-JEN YU; KANG-YI SU; CHAO-CHI HO; JIN-YUAN SHIH; Yang, Pan-Chyret al. |
| 臺大學術典藏 |
2018-09-10T15:17:48Z |
GM2-activator protein: A new biomarker for lung cancer
|
Potprommanee, L. and Ma, H.-T. and Shank, L. and Juan, Y.-H. and Liao, W.-Y. and Chen, S.-T. and Yu, C.-J.; CHONG-JEN YU; WEI-YU LIAO |
